Abstract Obsessive-compulsive disorder (OCD) is a chronic mental illness defined by recurrent, intrusive thoughts (called obsessions) and repetitive actions or ideas (called compulsions). Selective serotonin reuptake inhibitors and cognitive-behavioural therapy are currently the first-line treatments. Alternative therapeutic approaches must be developed because many patients still resist conventional medicines. There is increasing evidence that glutamate, rather than serotonin, is an essential factor in the pathophysiology of OCD. N-acetylcysteine (NAC) is a supplement that targets the glutamatergic system and is derived from the amino acids. Numerous preclinical and clinical trials suggest that NAC improves OCD sufferers. Numerous suggested processes, such as the control of various neurotransmitters, oxidative equilibrium and inflammatory mediators, have been brought up to explain the therapeutic benefits of NAC. This narrative review focuses on the effect of NAC, a glutamate-modulating agent, as an augmentation in the treatment of OCD. This article reviews the clinical trials, case reports and case series exploring using NAC for OCD. We thoroughly searched PubMed, Scopus and Google Search engines to identify the relevant trials published until December 2024. Critical words for searching included (‘N acetylcysteine’ OR NAC OR ‘Glutamatergic agents’) AND (‘Obsessive-compulsive disorder’ OR OCD). NAC’s clinical effectiveness has not been identified despite pre-clinical research suggesting that it improves the animal models of OCD. Although NAC is still a promising adjunct treatment option for OCD, more research with larger sample sizes is needed to confirm these results and develop conclusions about how effectively NAC works to improve the OCD symptoms.
Read full abstract